Testing a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a solid tumor that has spread or cannot be removed with surgery.
- You have at least one tumor that can be measured on a scan.
- Your doctor expects you to live at least 3 more months.
- You are in good enough health to do daily activities without help.
- You have not had an organ or bone marrow transplant.
- You have not had a live vaccine in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This study tests a new drug called ALK202, given with other medicines, to see if it is safe and works for people with non-small cell lung cancer. It targets certain proteins on cancer cells, and doctors will check your tumor for those markers to see if you might benefit.
This study tests an investigational drug called ALK-N001 for people with advanced solid tumors that have not responded to standard treatment or cannot tolerate it. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests a new pill, SY-12321, for people with advanced cancer that has a specific change called ALK. The study aims to see if the drug can shrink tumors or slow their growth, and it may be an option if you've already tried other ALK-targeting treatments.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.